Page 60 - 83_02

32. Elliott JH, Wightman F, Solomon A, et al. Activation
of HIV transcription with short-course vorinostat in
HIV-infected patients on suppressive antiretroviral
therapy. PLoS Pathog. 2014; 10: e1004473.
33. Lin S. HIV-1 reactivation induced by apicidin involves
histone modification in latently infected cells. Curr.
HIV Res. 2011;9:202–208
34. Nakajima H, Kim YB, Terano H, Yoshida M,
Horinouchi S. FR901228, a potent antitumor
antibiotic, is a novel histone deacetylase inhibitor.
Exper. Cell Res. 1998; 241: 126-33.
35. Wel DG, Chiang V, Fyne E, et al. Histone Deacetylase
Inhibitor Romidepsin Induces HIV Expression in CD4
T Cells from Patients on Suppressive Antiretroviral
Therapy at Concentrations Achieved by Clinical
Dosing. PLOS Pathogens 2014; 10: e1004071.
36. National Institute of Allergy and Infectious Diseases
(NIAID). A Phase I/II Study of Single Dose
Romidepsin in HIV-Infected Adults With Suppressed
Viremia on Antiretroviral Therapy to Assess Safety,
Tolerability, and Activation of HIV-1 Expression.
ClinicalTrials.gov. Bethesda (MD): National Library
of Medicine (US). Registered on August 28, 2013.
NLM Identifier: NCT01933594.
37. Bionor Immuno AS. An Open Phase I/IIa Study to
Evaluate the Safety and Effect of Therapeutic HIV-1
Immunization Using Vacc-4x/rhuGM-CSF, and HIV-
1 Reactivation Using Romidepsin, on the Viral
Reservoir in Virologically Suppressed HIV-1 Infected
Adults on cART. ClinicalTrials.gov. Bethesda (MD):
National Library of Medicine (US). Registered on
March 3, 2014. NLM Identifier: NCT02092116.
38. IrsiCaixa. An Open Label Phase I Trial to Evaluate the
Safety and Effect of HIVconsv Vaccines in
Combination With Histone Deacetylase Inhibitor
Romidepsin on the Viral Rebound Kinetic After
Treatment Interruption in Early Treated HIV-1
Infected Individuals (BCN02-Romi).
ClinicalTrials.gov. Bethesda (MD): National Library
of Medicine (US). Registered on November 9, 2015.
NLM Identifier: NCT02616874.
39. Mothe B et al. Viral control induced by HIVconsv
vaccines & romidepsin in early treated individuals.
Conference on Retroviruses and Opportunistic
Infections (CROI 2017), Seattle, abstract 119LB,
2017.
40. Julian H Elliott JH, McMahon JH, Chang CC, et al.
Short-term administration of disulfiram for reversal of
latent HIV infection: a phase 2 dose-escalation study.
The Lancet 2015; 2: 520-9.
41. Xing S, Bullen CK, Shroff NS, et al. Disulfiram
reactivates latent HIV-1 in a Bcl-2-transduced primary
CD4+ T cell model without inducing global T cell
activation. J Virol. 2011; 85: 6060-4.
42. Bocklandt S, Blumberg PM, Hamer DH. Activation of
latent HIV-1 expression by the potent antitumor
222 @Real Academia Nacional de Farmacia. Spain
M.ª del Carmen Avendaño López
promoter 12-deoxyphorbol 13-phenylacetate.
Antiviral Res. 2003; 59: 89-98.
43. a) Korin YD, Brooks DG, Brown S, Korotzer A, Zack
JA. Effects of prostratin on T-cell activation and
human immunodeficiency virus latency. J Virol. 2002;
76: 8118-23. b) Williams SA, Chen LF, Kwon H, et
al. Prostratin antagonizes HIV latency by activating
NF-kB. J Biol Chem. 2004; 279: 42008-17. c) Wender
PA, Kee JM, Warrington JM. Practical synthesis of
prostratin, DPP, and their analogs, adjuvant leads
against latent HIV. Science 2008; 320: 649-52.
44. a) Mehla R, Bivalkar-Mehla S, Zhang R, et al.
Bryostatin modulates latent HIV-1 infection via PKC
and AMPK signaling but inhibits acute infection in a
receptor independent manner. PLoS One 2010; 5:
e11160. b) Pérez M, de Vinuesa AG, Sanchez-
Duffhues G, et al. Bryostatin-1 synergizes with
histone deacetylase inhibitors to reactivate HIV-1
from latency. Curr HIV Res. 2010; 8: 418-29. c)
DeChristopher BA, Loy BA, Marsden MD, et al.
Designed, synthetically accessible bryostatin
analogues potently induce activation of latent HIV
reservoirs in vitro. Nature Chem. 2012; 4: 705-10.
45. Abreu CM, Price SL, Shirk EN, et al. Dual role of
novel ingenol derivatives from Euphorbia tirucalli in
HIV replication: inhibition of de novo infection and
activation of viral LTR. PLoS One 2014; 9: e97257.
46. (a) Filippakopoulos P, Qi J, Picaud S, et al. Selective
inhibition of BET bromodomains. Nature 2010; 468:
1067-73. (b) Filippakopoulos P, Knapp S. Targeting
bromodomains: epigenetic readers of lysine
acetylation. Nature Rev Drug Discov 2014; 13: 337-
56. (c) Gallenkamp D, Gelato K A, Haendler B,
Weinmann H. Bromodomains and Their
Pharmacological Inhibitors. ChemMedChem 2014; 9:
438-64. (d) Sánchez R, Meslamani J, Zhou MM. The
bromodomain: from epigenome reader to druggable
target. Biochim Biophys Acta 2014; 1839: 676-85.
47. Avendaño C. BET inhibitors. The odd compound (+)-
JQ1. An R Acad Farm. 2015; 81: 214-20.
48. Zhu J, Gaiha GD, John SP, et al. Reactivation of
Latent HIV-1 by Inhibition of BRD4. Cell Rep. 2012;
2: 807-16.
49. a) Scheller C, Ullrich A, McPherson K, et al. CpG
oligodeoxynucleotides activate HIV replication in
latently infected human T cells. J Biol Chem. 2004;
279: 21897-902. b) Thibault S, Imbeault M, Tardif
MR, Tremblay MJ. TLR5 stimulation is sufficient to
trigger reactivation of latent HIV-1 provirus in T
lymphoid cells and activate virus gene expression in
central memory CD4+ T cells. Virology 2009; 389:
20-5. c) Schlaepfer E, Speck RF. TLR8 activates HIV
from latently infected cells of myeloid-monocytic
origin directly via the MAPK pathway and from
latently infected CD4+ T cells in directly via TNF-a. J
Immunol. 2011; 186: 4314-24.